145 related articles for article (PubMed ID: 25849006)
1. Limb girdle weakness responding to salbutamol: an Indian family with DOK7 mutation.
Khadilkar S; Bhutada A; Nallamilli B; Hegde M
Indian Pediatr; 2015 Mar; 52(3):243-4. PubMed ID: 25849006
[TBL] [Abstract][Full Text] [Related]
2. Salbutamol therapy in congenital myasthenic syndrome due to DOK7 mutation.
Lorenzoni PJ; Scola RH; Kay CS; Filla L; Miranda AP; Pinheiro JM; Chaouch A; Lochmüller H; Werneck LC
J Neurol Sci; 2013 Aug; 331(1-2):155-7. PubMed ID: 23790237
[TBL] [Abstract][Full Text] [Related]
3. Effective Treatment With Albuterol in DOK7 Congenital Myasthenic Syndrome in Children.
Tsao CY
Pediatr Neurol; 2016 Jan; 54():85-7. PubMed ID: 26552645
[TBL] [Abstract][Full Text] [Related]
4. Salbutamol benefits children with congenital myasthenic syndrome due to DOK7 mutations.
Burke G; Hiscock A; Klein A; Niks EH; Main M; Manzur AY; Ng J; de Vile C; Muntoni F; Beeson D; Robb S
Neuromuscul Disord; 2013 Feb; 23(2):170-5. PubMed ID: 23219351
[TBL] [Abstract][Full Text] [Related]
5. Salbutamol-responsive limb-girdle congenital myasthenic syndrome due to a novel missense mutation and heteroallelic deletion in MUSK.
Gallenmüller C; Müller-Felber W; Dusl M; Stucka R; Guergueltcheva V; Blaschek A; von der Hagen M; Huebner A; Müller JS; Lochmüller H; Abicht A
Neuromuscul Disord; 2014 Jan; 24(1):31-5. PubMed ID: 24183479
[TBL] [Abstract][Full Text] [Related]
6. β2-Adrenergic receptor agonists ameliorate the adverse effect of long-term pyridostigmine on neuromuscular junction structure.
Vanhaesebrouck AE; Webster R; Maxwell S; Rodriguez Cruz PM; Cossins J; Wickens J; Liu WW; Cetin H; Cheung J; Ramjattan H; Palace J; Beeson D
Brain; 2019 Dec; 142(12):3713-3727. PubMed ID: 31633155
[TBL] [Abstract][Full Text] [Related]
7. DOK7 congenital myasthenic syndrome.
Palace J
Ann N Y Acad Sci; 2012 Dec; 1275():49-53. PubMed ID: 23278577
[TBL] [Abstract][Full Text] [Related]
8. COLQ-Related Congenital Myasthenic Syndrome and Response to Salbutamol Therapy.
Padmanabha H; Saini AG; Sankhyan N; Singhi P
J Clin Neuromuscul Dis; 2017 Mar; 18(3):162-163. PubMed ID: 28221310
[No Abstract] [Full Text] [Related]
9. DOK7 congenital myasthenic syndrome: case series and review of literature.
Ziaadini B; Ghaderi Yazdi B; Dirandeh E; Boostani R; Karimi N; Panahi A; Kariminejad A; Fadaee M; Ahangari F; Nafissi S
BMC Neurol; 2024 Jun; 24(1):211. PubMed ID: 38907197
[TBL] [Abstract][Full Text] [Related]
10. Familial Dok7 congenital myasthenic syndrome responsive to salbutamol.
Maramattom BV; Patil R; Thomas J
Neurol India; 2014; 62(3):313. PubMed ID: 25033858
[No Abstract] [Full Text] [Related]
11. Slow channel congenital myasthenic syndrome responsive to a combination of fluoxetine and salbutamol.
Finlayson S; Spillane J; Kullmann DM; Howard R; Webster R; Palace J; Beeson D
Muscle Nerve; 2013 Feb; 47(2):279-82. PubMed ID: 23281026
[TBL] [Abstract][Full Text] [Related]
12. DOK7 limb-girdle myasthenic syndrome mimicking congenital muscular dystrophy.
Mahjneh I; Lochmüller H; Muntoni F; Abicht A
Neuromuscul Disord; 2013 Jan; 23(1):36-42. PubMed ID: 22884442
[TBL] [Abstract][Full Text] [Related]
13. Delineation of molecular characteristics of congenital myasthenic syndromes in Indian families and review of literature.
Mishra S; Nair KV; Shukla A
Clin Dysmorphol; 2023 Oct; 32(4):162-167. PubMed ID: 37646703
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effect of albuterol in congenital myasthenic syndrome with epsilon-subunit mutations.
Sadeh M; Shen XM; Engel AG
Muscle Nerve; 2011 Aug; 44(2):289-91. PubMed ID: 21721016
[TBL] [Abstract][Full Text] [Related]
15. Beta-2 Adrenergic Receptor Agonists Enhance AChR Clustering in C2C12 Myotubes: Implications for Therapy of Myasthenic Disorders.
Clausen L; Cossins J; Beeson D
J Neuromuscul Dis; 2018; 5(2):231-240. PubMed ID: 29865088
[TBL] [Abstract][Full Text] [Related]
16. Phenotypical spectrum of DOK7 mutations in congenital myasthenic syndromes.
Müller JS; Herczegfalvi A; Vilchez JJ; Colomer J; Bachinski LL; Mihaylova V; Santos M; Schara U; Deschauer M; Shevell M; Poulin C; Dias A; Soudo A; Hietala M; Aärimaa T; Krahe R; Karcagi V; Huebner A; Beeson D; Abicht A; Lochmüller H
Brain; 2007 Jun; 130(Pt 6):1497-506. PubMed ID: 17439981
[TBL] [Abstract][Full Text] [Related]
17. Effect of salbutamol on neuromuscular junction function and structure in a mouse model of DOK7 congenital myasthenia.
Webster RG; Vanhaesebrouck AE; Maxwell SE; Cossins JA; Liu W; Ueta R; Yamanashi Y; Beeson DMW
Hum Mol Genet; 2020 Aug; 29(14):2325-2336. PubMed ID: 32543656
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis of DOK7 congenital myasthenic syndrome during pregnancy: A case report and literature review.
Fernandes M; Caetano A; Pinto M; Medeiros E; Santos L
Clin Neurol Neurosurg; 2021 Apr; 203():106591. PubMed ID: 33714798
[TBL] [Abstract][Full Text] [Related]
19. Congenital myasthenia syndrome with demyelinating sensorimotor neuropathy responsive to salbutamol monotherapy: a novel clinical phenotype of CHRNE mutation.
Ghosh R; Dubey S; Roy D; Mayo S; Benito-León J
Neurol Sci; 2024 Jul; 45(7):3555-3558. PubMed ID: 38411853
[No Abstract] [Full Text] [Related]
20. DOK7 myasthenic syndrome with subacute adult onset during pregnancy and partial response to fluoxetine.
Santos M; Cruz S; Peres J; Santos L; Tavares P; Basto JP; Salgado V; Valverde AH
Neuromuscul Disord; 2018 Mar; 28(3):278-282. PubMed ID: 29395672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
